4 Jul 2008 07:00
Embargoed Release: 07:00hrs Fri 4th July 2008
Nanoscience Inc. ('Nanoscience' or 'the Group') Toumaz Signs Significant Licensing Agreement to Develop its Sensium¢â€ž¢ Technology in Sport
Nanoscience, the specialist niche investor in emerging technologies with strong commercial propositions for the healthcare and electronic sectors, is pleased to announce that its wholly-owned subsidiary Toumaz Technology Limited (`Toumaz'), has signed a new licensing agreement with a sports-focussed business originating from the Far East (the `Partner'), to develop Toumaz's Sensium¢â€ž¢ brand globally by establishing its technology in the sports industry. The agreement is initially worth ‚£1.5 million; ‚£500,000 net has just been received with the remainder to be paid within the next six months, pending the fulfilment of certain obligations by Toumaz.
Under the agreement, the Sensium¢â€ž¢ will initially target the football and horse racing fields where a development programme is currently underway; strong relationships with contacts and potential clientele have been established and preliminary discussions have commenced to develop the Sensium¢â€ž¢ as a premium professional sports product. In addition, Toumaz is cultivating independent relationships in the rugby sports sector.
The Sensium¢â€ž¢ is a low-cost, end-to-end solution that measures human key vital signs such as ECG, body temperature, respiration rate and physical movement on a continuous and real time basis using unobtrusive, small and light wearable devices that links wirelessly to a comprehensive data management system. Under the agreement, it is envisaged that the Sensium¢â€ž¢ will at first be developed as a training aid with the aim of building a substantial and detailed data bank, which would become an essential tool to support sports professionals and their trainers.
The agreement highlights the adaptability of Toumaz's Sensium¢â€ž¢ technology; it has made impressive headway in the healthcare sector as relationships and strategic partnership agreements have been signed with Texas Instruments Incorporated and Cardinal Health to develop and market Sensium¢â€ž¢ branded products that are currently undergoing rigorous market testing and FDA approval processes.
Guy Spelman, chief executive officer at Nanoscience, commented:
`The new licensing agreement represents an exciting opportunity for Toumaz and its increasingly recognised Sensium¢â€ž¢ technology. We believe the Sensium¢â€ž¢ is the ideal training aid to optimise the latent talent of sports professionals by monitoring their health and fitness and capturing this data. Toumaz's new Partner offers both extensive and well respected channels to the sports industry and we at Nanoscience fully anticipate that the two parties working in tandem will establish the Sensium¢â€ž¢ as a formidable elite brand going forward.'
-Ends-
Further information:
Guy Spelman Nanoscience Inc. 07767 338 967
Tim Goodman Ambrian Partners 020 7634 4711
Vikki Krause Hansard Group 020 7245 1100
www.hansardgroup.co.uk
- Ends -
About Toumaz Technology (www.toumaz.com)
Toumaz Technology Limited is the leading provider of ultra-low power wireless infrastructure for body monitoring solutions. Toumaz's ultra low-power smart sensor interface and transceiver platform - the Sensium¢â€ž¢ - enables non-intrusive, real-time wireless monitoring of multiple vital signs for a wide range of healthcare, sports and lifestyle management applications.
Based on Toumaz's patented ultra-low power Advanced Mixed Signal (`AMx¢â€ž¢') technology, the Sensium¢â€ž¢ provides the enabling technology to connect the mobile individual to healthcare providers and sports trainers - simply, affordably and unobtrusively.
vendor